Report and financial statements for the year ended 31 December 2021

Multiple Sclerosis International Federation

(A company limited by guarantee)

Company registration number:	05088553
Charity registration number:	1105321
Registered address:	Skyline House, 200 Union Street, London SE1 0LX

Contents

Introduction

During 2021, the MS International Federation and its members – the global MSIF Movement – together with all the people affected by MS wherever they lived in the world, continued to face huge uncertainties and challenges created by the COVID-19 pandemic.

Whilst MSIF was fortuitous in having introduced a virtual fundraising campaign that was not affected by the pandemic, many of MSIF's member organisations lost income and with that experienced staff. This diminished their capacity to support people affected by MS in their own country, fund highly necessary research or to contribute to global work within the MSIF movement.

Despite the pandemic we have been able to make progress towards the objectives we have set ourselves, supporting collaboration in research, advocating for improved access to treatments and healthcare, providing information and working with our members and other MS organisations to build a stronger broader MS movement.

This report provides an overview of the progress made by the Movement toward the objectives in our strategy "Together we are Stronger than MS"

At the heart of our strategy is a unified vision. This vision guides not just the MSIF secretariat, but the entire MS Movement which works together to pursue its aims. Through this approach of collaboration and active engagement, MSIF's members and other MS organisations can mutually benefit from the expertise and resources of the other members and these resources also contribute to global work and collaborative projects.

Our movement hosts many countries, many cultures and many different realities of what it means to live with MS. In this report, you will see parts of the movement that have contributed, as well as the impact on the lives of people affected by MS around the world. We are very grateful for all the organisations that, and health care professionals and researchers who, in spite of very difficult challenges, continue their commitment to work together and share their expertise and resources with the whole movement, driven on by the needs of people affected by MS – and their and our ultimate dream: a world without MS.

Mai Sharawy

Chair

Who we are and what we do

The Strategy for 2017-2021

'Together we're stronger than MS' is the strategy for the whole global MSIF movement.

The focus of this strategy is to mobilise the entire MSIF movement; organisations, people affected by MS, volunteers and staff, to achieve our common mission: To bring the world together to improve the quality of life of everybody affected by MS and to end MS forever.

We are building a stronger, broader, global movement made up of effective MS organisations, engaged individuals and strategic international collaborations. Together we tackle challenges for people affected by MS in countries rich and poor.

Our aims, objectives and activities

Our five aims show the impact we aim to achieve as a movement over 10 to 15 years. These aims are connected and support each other. In order to work towards these aims, we have identified a number of objectives and actions for the five-year strategic period. See more: www.msif.org/about-ms/our-strategy/. The table below outlines those we set out to achieve in 2021.

MSIF - 2021 priorities

Long term Aims in the 2017-2021 Strategy	2021 objectives and actions towards these aims
Better scientific understanding leading to new ways to treat, prevent and stop MS.	• Advance systems for enabling data sharing, with a focus on Patient Reported Outcomes and the relationship between MS and COVID-19. • Continue to engage member organisations in and facilitate global communications about the Progressive MS Alliance. • Fill gaps in the MS research workforces throughout the world.
Improved access to effective treatments and health care.	• Continue work toward ensuring access to DMTs, including a new application for the WHO's Essential Medicines List. • Use the Atlas to collect some more global data and publish the data gathered in 2020 in relation to access to treatment.
Access to accurate and trustworthy information and resources to make informed decisions to live well with MS.	• Repurpose and translate one or two materials for adaptation and use around the world. • Maintain networks of membership staff and volunteers in communications.
Positive changes in policies and practices, attitudes and behaviours that are obstacles to living well with MS	• Develop advocacy tools for national, local and individual action, in particularly by coordinating World MS Day and continuing the work on an update of the Atlas of MS.
A stronger, broader MSIF movement made up of effective MS organisations, engaged individuals and strategic international collaborations	• Strengthen MS organisations in countries with challenging socio-economic conditions, with a continued focus on the Arab region, Latin America and India. • Enhance the effectiveness of members and MSIF, including through our International Networking meetings. • Implement the 'more than one member per country' policy.

Contribution of volunteers

One volunteer supports the MSIF Secretariat in the organisation of its biannual international networking meetings. Our trustees are unpaid volunteers. Around the world many other members of committees and working groups, including people affected by MS and health care professionals, also contribute to our common global work.

How we measure and assess success

MSIF sets annual milestones and longer term objectives for each project and for the strategy and organisation as a whole, the latter is available to the public in MSIF's 2017-2021 Strategy on www.msif.org/about-us/reports-and-resources

We regularly monitor and evaluate projects against these indicators in order to learn and improve our work, ensure accountability and good governance. Annual reports are prepared for major funders, with six-monthly updates provided to the board and all members through a Strategy Progress Report. Our annual trustee report and accounts are published on our website.

Methods we use to assess and measure success include:

- Surveys of our membership and/or the global MS community e.g. World MS Day evaluation survey, survey of our research grant recipients;
- Number of subscribers to our e-newsletters;
- Number of new MS organisations fulfilling MSIF membership criteria;
- Number of downloads of our information resources, advocacy publications and toolkits and various numerical indicators in relation to MSIF's social media;
- Number of MS organisations and individuals taking part in our events e.g. World MS Day or various webinars
- Comparison of organisational self-assessments made during capacity building projects;
- Qualitative feedback gathered via focus group discussions and semi-structured interviews;
- Reports by external consultants on the results and effectiveness of MSIF's projects;
- Logs of any complaints received and our response to them;
- Evaluation forms from training, conference and meeting attendees.

Ultimately MSIF's purpose is to benefit people with and affected by MS around the world, both through our member organisations and network but also directly, especially where no such MS organisations exist. To help assess our success, our People with MS Advisory Committee provides advice to the board on any issues in relation to the needs of people with and affected by MS. Most of our project work groups have members who have or are affected by MS, as does our Board of Trustees. We also consult with a wider pool of people with and affected by MS.

Our complaints policy and procedure are sign-posted on our website. We define a complaint in broad terms as 'any expression of dissatisfaction about any aspect of MSIF and its work with the global MSIF movement'. In 2021 we received 14 complaints, compared to 43 in 2020.

Grant making policy

Once the implications of the COVID-19 pandemic became clear in early 2020 special conditions were attached to any of the grants provided by MSIF. Those related to safeguarding the wellbeing of those participating in or implementing the projects or activities covered by the grants. In the majority of cases this meant that only virtual projects have been supported and that activities which had been planned to take place in person, or included national or international travel, were either cancelled or undertaken in a virtual manner. In some cases, such as some of the research related grants, the implementation of the grants was postponed. These conditions were somewhat relaxed during the course of 2021.

COVID-19 Response Grants

Many of MSIF's member organisations faced financial challenges during the COVID-19 pandemic. On the one hand people affected by MS had many additional needs to be met. On the other hand, income in many countries was less due to the difficulties of in-person fundraising. As an exceptional measure MSIF provided COVID-19 Response Grants to MSIF member organisations, and members of its European sister organisation, the European MS Platform (EMSP) with one-off support for the following areas:

- Protection of minimum organisational infrastructure needed to maintain essential/core programmes, projects or activities, whilst offering a reduced/adapted service because of the COVID-19 pandemic. To help the organisation cope with the current situation, or short-term costs.
- Specific COVID-19 project work.
- Preparations for future change and growth during and after COVID-19.

A special panel was convened to decide on the allocation of the grants taking into account several criteria, including:

- There is clear impact for people with MS;
- The organisation has made efforts to close the budget gap (such as seeking emergency government funding, corporate or foundation funding, using reserves, or making operational cuts or changes to fundraising;
- The organisation's track record shows they have the skills, systems and experience necessary for project/activity delivery;
- There is evidence of good governance, accountability and transparency;
- The organisation prioritises the safety and wellbeing of their staff, volunteers and people affected by MS; also considering the safety risks for people involved in Initiative-funded activities, including measures to mitigate the risk.

MSIF approached all the healthcare companies with which it is in contact to financially support this effort, raising £570,528 in the course of (and accounted for in) 2020. At the end of 2020 grants were allocated to 18 MS member organisations which undertook their projects covered by the grants in the course of 2021. The grants were allocated to organisations in Argentina, Austria, Belgium, Brazil, Cyprus, France, Germany, Greece, Guatemala, India, Ireland, Latvia, Poland, Portugal, Spain, Switzerland and Tunisia.

Capacity building grants

Capacity building grants aim to support emerging organisations, or representatives of those organisations, in countries with economic challenges and/or a less well-developed civil society sector and are awarded on the judgement of MSIF staff. These grants are either given to registered organisations, emerging MS support structures or to service providers/consultants. In exceptional cases grants are paid to intermediary non-governmental organisations or individuals to help them undertake capacity building work to help create a local MS support structure.

The grants are given for travel to MSIF or other meetings and training events or for time-limited project work, such as production of materials, training opportunities or awareness-raising or advocacy activities. They can include costs for staff or consultants.

Travel grants to MSIF meetings normally require that grantees pay part of the costs themselves or find match- funding.

Project or activity grants are awarded through a thorough and (where appropriate) competitive process, through public tendering and/or calls for applications.
Such criteria may involve both organisational and country factors, such as:

- Due diligence in relation to the organisations involved (including: audited accounts; official registration documents; satisfactory capacity and processes to implement the grant)
- Organisation type (patient-led/health professional-led)
- Organisations' responsiveness and readiness
- MS prevalence rate
- Accessibility to treatment by people with MS

- Travel risk
- World Bank country classifications (e.g. per capita income and poverty rates).

These grants are decided by a panel of staff members of the MSIF Secretariat and formalised in grant agreements. They are normally provided in instalments dependent on reporting on progress towards objectives and expenditure.

Some other grants, for example those relating to World MS Day, are used to support a wider range of organisations and members.

Research grants and awards

Research grants aim to encourage or facilitate international collaboration in medical or socio economic research into MS and through this the search for understanding the cause, for better treatment and ultimately to end MS.

Grants may be provided to institutions, groups of researchers or individual researchers. The grants to individuals have a strong emphasis on researchers from emerging countries and also aim to reinforce research and clinical capacity in such countries, as well as the development of MS organisations.

Grants may be given in the form of:

- Fellowships or travel grants for researchers to spend time gaining experience in another country (McDonald Fellowship and Du Pré grant)
- Awards in recognition of life time achievements or outstanding research contributions (Charcot Award and Young Investigator Award)
- Ad-hoc contributions to certain international research collaborations

Calls for proposals are normally publicly distributed within the research community and publicised on MSIF's website and mostly judged on a competitive basis by panels of members from MSIF's International Medical and Scientific Board (IMSB).

Ad hoc grants may be made on the basis of established priorities in MSIF's strategy and decided by the CEO, seeking advice from the chair of the IMSB and/or its Executive Committee or other qualified researchers.

Criteria used to decide on grants may include:

- Scientific merit of the proposals
- Relevance to MSIF's strategic priorities
- Income category of the researcher's country ('emerging countries': with a low, lower middle or upper middle income as defined by the World Bank)
- Extent of international and collaborative involvement

Where grants are awarded for the duration of more than one year they are paid in instalments, subject to reporting on progress and expenditure.

Governance for a global movement

Governing document and Board of Trustees

Multiple Sclerosis International Federation is a charity established under a Memorandum and Articles of Association and incorporated as a company limited by guarantee and not having a share capital on 30 March 2004. The Federation was registered with the Charity Commission on 5 August 2004.

On 21 July 2021 a special written resolution was agreed and passed to amend the Articles of Association, with the main changes being the introduction of a Triannual General Meeting, at which Board members are elected, thereby extending each normal term of board membership from 2 till 3 years. The resolution also amended the Articles to provide for Annual General Meetings in the years when no Triannual General Meetings are taking place.

On 20 October 2021 at the Annual General Meeting of MSIF's Council a new Board slate was approved.

For the purpose of the Companies Act 2006, the Board of trustees is regarded as the Board of Directors of the company. The trustees of the company throughout the period are as follows:

Mai Sharawy (Egypt) **Chair**

Marie Vaillant (Canada, retired October 2021) **Vice Chair**

Martin Stevens (UK) **Secretary**

Victoria Annis (UK) **Treasurer**

Johana Bauer (Argentina, appointed October 2021)	Mario Battaglia (Italy)
Desmond Graham (Australia)	Ava Battles (Ireland, appointed October 2021)
Martinus Desmet (Belgium, appointed October 2021)	Alessandro Perfetti (Italy, retired October 2021)
Charles van der Straten Waillet (Belgium, retired October 2021)	Wissam Al Haj (Lebanon, retired October 2021)
Dr Brenda Banwell	Liesbeth Kooij (Netherlands)
Pamela Valentine (Canada)	Pedro Carrascal (Spain)
Christian Bardenfleth (Denmark, retired October 2021)	Ana Torredemer (Spain)
Klaus Høm (Denmark)	Nick Moberly (UK)
Guillaume Courault (France)	Andrea Prato (Uruguay)
Herbert Temmes (Germany)	Peter Galligan (USA)
Dimitra Kalogianni (Greece)	Kim Phillips (USA)
Viresh Oberoi (India)	Cynthia Zagieboylo (USA)

Methods for recruiting, appointing, training trustees

The Council, MSIF's supreme governing body, elects a Nominating Committee. The Nominating

Committee reviews skills required for the Board and invites MSIF member organisations and relevant others to nominate candidates. It reviews submissions, interviews candidates when necessary and meets to discuss and finalise a slate of candidates to fill all Board positions. The Committee distributes supporting papers to Council members and submits them with the slate for discussion and election. Under the Articles of Association, the members of the Board of Trustees are elected at the triennial Council Meeting. The Board shall consist of no less than three members. Guidance is in place for rotation of Board members.

New trustees receive written induction information upon appointment and attend an induction within the first six months of appointment.

Charity Code of Governance

As a global organisation based in the United Kingdom, MSIF follows and benefits from the regulatory framework and standards in the highly developed Charity sector in the UK adding elements that reflect its international character.

The Board has adopted the key principles of the Charity Code of Governance, which is considered an important standard for governance in the UK charity sector.

There is a recommendation within the code for board size of between 5 – 12 trustees. In 2021 our board had 23 members (after 20 October). We have members and organisations we work with in more than 90 countries and continue to grow our reach, including in areas where support for people affected by with MS is patchy. It is our opinion, that having this larger board gives us greater diversity and is more representative of the communities and countries we operate in. Diversity and inclusion provide more breadth of opinion and experience in the discussions and decision making that take place across the organisation. The Board of trustees values people’s differences and is fully committed to encouraging diversity. Our aim is to strive to have at least 25% of seats on the board filled by people with MS. In 2021, with 5 out of the 23 trustees being persons with MS. It is important that their voices are heard in the Board, and we want to send a strong message to the outside world that all operations of the Federation support this.

During 2021 we have set up a task force to explore any existing barriers and present recommendations to the board in relation to equality, diversity and inclusion in relation to governance and the operations of the Federation.

Risks and risk-management

The trustees have given consideration to the major risks to which the charity is exposed and satisfied themselves that systems or procedures are established in order to manage those risks.

Every six months the trustees review the major governing, operational and financial risks which the Federation faces and adjust mechanisms to lessen these risks when judged necessary and consider how to manage them when they might occur. The risk register gets updated accordingly.

Some of the risks are more temporary, other risks are more permanent and include the risk of individual health care companies’ changes in strategy and reducing or stopping grants to MS patient organisations.

Equally the risk of sudden political instability or of security or disaster in a country where we operate, including the risk to staff is always present, although in 2021, due to the absence of international travel due to COVID-19 the risk associated with this was very small. Only one international journey was undertaken. In normal years control procedures include following foreign office travel advice and use of insurance company security briefings, as well as adequate travel and event insurance.

Another permanent risk is that of adverse publicity, due to a failing for example in governance or fundraising practice, leading to reduced trust and confidence, for example amongst beneficiaries and funders. Control procedures include following MSIF’s governance procedures and fundraising policies, such as those in relation to receiving funding from the healthcare industry and standards set by relevant regulators.

The COVID-19 situation continues to pose risks in various ways, albeit less than in 2020. They include a reduction in future income from our membership fees as members face lower income from the inability to hold in person fundraising events and our ability to deliver some of our collaborative overseas projects due to continued travel restrictions. All our in-person conferences and meetings were cancelled for all of 2021 and the first in-person Board meeting is now envisaged for October 2022. Given the international nature of the movement, this will be kept under review.

Management and structure

The structure of the organisation consists of a Council, made up of representatives from its member organisations, that elects the Board of Trustees. In 2021, the trustees held 4 virtual meetings, in March, June, October and December.

Trustees are responsible for the overall strategic direction of the charity while decisions on tactical means to achieve these objectives are taken by the Chief Executive in conjunction with staff and with input from people affected by MS, member organisations and other stakeholders throughout the world.

Additionally, operational working groups, often made up from staff and or volunteers from Member Organisations, take on responsibilities for specific projects, either reporting to the CEO or directly to the board of trustees depending on the nature of each project.

Pay and remuneration

A salary review was undertaken in 2021, comparing MSIF to other comparable organisations in the UK. This resulted in a new pay and remuneration system, which includes all staff and the CEO.

The system includes annual increases in pay and remuneration, including inflation and increments. Ratio between highest and lowest paid permanent staff in the organisation is a maximum of 4.

Key management personnel

Chief Executive Peer Baneke

Deputy CEO Ceri Angood Napier / Nick Rijke

Bankers	Auditors	Solicitors
Coutts & Co. 440 Strand, London WC2R 0QS CCLA Investment Management Ltd, COIF Charity Funds, Senator House, 85 Queen Victoria Street London EC4V 4ET	Moore Kingston Smith, Devonshire House 60 Goswell Road London EC1M 7AD	Collyer-Bristow LLP, 4 Bedford Row, London WC1R 4DF

Public benefit

The trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit. In line with this we are committed to providing high quality information and services to the global MS community. As well as offering services and information for our network of MS organisations, the vast majority of our materials containing information for people with and affected by MS, clinicians, and advocates can be accessed by the public via our website www.msif.org.

In agreeing our activities for each year we have regard to the legal responsibilities outlined in the Charity Commission’s general guidance on public benefit. The trustees always ensure that the programmes are in line with our charitable objects as set out in MSIF’s governing document the Articles of Association.

The benefits of our activities for individuals are available worldwide and have most relevance in those areas where the incidence of MS is highest. They are not dependent on membership of MSIF or of one of the national MS organisations. They are directed in the main to people with MS, their caregivers, their families and others affected by it.

Trustees report

The trustees present their report and financial statements for the period ended 31 December 2021. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" issued 2015 in preparing the annual report and financial statements of the charity.

MSIF's progress against 2021 priorities

In MSIF's Report and Financial statements for the year ending 2021 we set out objectives and actions for 2021 towards the aims in our 5 year strategy. Here we restate those objectives and report on our progress towards them in 2021.

To contribute to our aim of: Better scientific understanding leading to new ways to treat, prevent and stop MS.

We set objectives for 2021 to:

- Advance systems for enabling data sharing, with a focus on Patient Reported Outcomes and the relationship between MS and COVID-19.
- Continue to engage member organisations in and facilitate global communications about the Progressive MS Alliance.
- Fill gaps in the MS research workforces throughout the world.

Data sharing

The COVID-19 and MS Global Data Sharing Initiative (GDSI) was established in March 2020 in partnership with the MS Data Alliance to meet an urgent need for data about possible impacts of MS or the medicines used in MS on the COVID-19 disease course or on the risks of attracting COVID-19. It has 21 data partners from across the world, and has gathered information on COVID-19 on more than 10,000 people with MS, from 80 countries. The findings of the data sharing initiative helped a consensus group of healthcare professionals to develop advice for people with MS in relation to COVID-19 (see below under our aim of *'Access to accurate and trustworthy information and resources to make informed decisions to live well with MS'*). The project which was originally intended to end in 2020, was extended throughout 2021. Results were presented at the congress of the European Committee for Treatment and Research in MS (ECTRIMS) in October and published in Neurology.

Our collaboration with the European Charcot Foundation on international Patient Reported Outcomes (PROMS), with the Italian MS Society (AISM) as lead agency has continued throughout 2021. Outcomes of clinical trials and data collected in registries often focus on outcome measures reported by healthcare professionals. This initiative aims to determine which outcomes reported by patients are the most meaningful, effective and useful for people with MS, researchers, clinicians, regulatory bodies and in public healthcare more generally and how these can be used to make a real difference in the quality of life of people with MS. Around 60 experts from the clinical world, academia (including health economy), healthcare industry and patient organisations as well as people affected by MS are involved in various working groups to forge the strategy to achieve our aims. An Engagement Coordination Team with a core of people affected by MS aims to ensure the engagement of people affected by MS around the world throughout the project. The ECT is co-chaired by a person living with MS from South Africa and the Assistant Director of Research of the UK MS Society. On 13 November the PROMS Initiative Annual Event 2021 took place in Baveno, Italy, with participation from many stakeholders, including people affected by MS, researchers, clinicians, MS societies, and those linked to industry and regulatory bodies.

Progressive MS Alliance

We have continued to play an active role in the International Progressive MS Alliance, our collaboration with many of our member organisations, to progress the search for understanding and treatment of progressive MS. In February a meeting of CEOs of MSIF's member organisations and MSIF board members, participated in a meeting to contribute to the new strategy of the Alliance. At the end of 2021, 19 MSIF members had participated in pooling funds for the Alliance.

Fill gaps in the pipeline of the MS Research workforce

MSIF's McDonald Fellowships and Du Pré Grants enable promising young researchers from countries with low, lower middle or upper middle income (as defined by the World Bank) to undertake extensive research programmes (McDonald) or short working visits (Du Pré) at global research centres of excellence. This helps to enhance the skills of researchers and clinicians from such countries and promotes more globally representative research collaborations. We awarded 3 new McDonald Fellowships: with researchers from Egypt, Brazil and Argentina going to the United Kingdom, the Netherlands and the USA respectively, and 3 new Du Pré grants, with researchers from Tunisia, Brazil and Iran going to France, Germany and Canada respectively.

Several of our research grants were supported by the Foundation for Support of MS Research (ARSEP, France) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

To contribute to our aim of: Improved access to effective treatments and healthcare. We set objectives for 2021 to:

- Continue work toward ensuring access to Disease Modifying Treatments (DMTs), including to a new application for the WHO's Essential Medicines List.
- Use the Atlas to collect some more global data and publish the data gathered in 2020 in relation to access to treatment.

In 2018 we submitted a proposal to the World Health Organisation (WHO) to put three disease modifying treatments (DMTs) onto its 'Essential Medicines' (EML) list. In 2019 the WHO informed us that we had not been successful and requested a revised proposal, including an analysis of two named off-label medicines. In 2020 we further developed the methodology for this work, gathered people with MS, experts from our members and from the research community from different parts of the world and began to collaborate with several research institutions in order to shape our new EML application. We intensified our dialogue with parts of the WHO Secretariat and gathered a panel to formulate relevant treatment guidelines for the medicines involved. In 2020 this work continued with a crucial first result of this work, the publication of an article setting out general principles for the ethical use of off-label DMTs for treating MS and a process to assess existing evidence and develop recommendations for their use.

In addition to this work we convened people with MS, member organisations, our International Medical and Scientific Board (IMSB) and our International Working Group on Access and submitted a commentary to actively influence the WHO Global Action Plan on epilepsy and other neurological disorders

To contribute to our aim of: A stronger, broader MSIF movement made up of effective MS organisations, engaged individuals and strategic international collaborations

We set objectives for 2021 to:

- Strengthen MS organisations in countries with challenging socio-economic conditions, with a continued focus on the Arab region, Latin America and India.
- Enhance the effectiveness of members and MSIF, including through our International Networking meetings.
- Implement the 'more than one member per country' policy.

Strengthen MS organisations in countries with challenging socio-economic conditions

MSIF's capacity building programmes focused on Latin-America, the Arab region and India. For Latin-America and the Arab region the work consists of region-wide activities (such as regional meetings and information sharing) and a focus on a small group of countries in each region. In 2021 all activities took place in a virtual way.

Latin America

In 2021 we continued working with MS organisations in Brazil (ABEM), funding a communications agency to help them develop a communications strategy) and Uruguay (EMUR, on the creation of a self-navigation tool for people living with MS: the MS Compass.

EMA Argentina, APEMED Paraguay, RENACER Dominican Republic and ALEM Colombia were awarded small grants so that they could carry out digital fundraising campaigns. EMA used its grant to take part in MSIF's global TheMay50K global fundraising campaign – the first participant from the region.

As 2021 was the end of the 2027-2021 LATAM strategy, an evaluation took place, including of the perspectives of key stakeholders about the role of MSIF. This will feed into the development of a new multi-year strategy.

Arab region

MSIF's fundraising capacity building work with three Moroccan MS organisations ended in early 2021. We worked with Arfa MS Society in Saudi Arabia to produce issue 28 of the regional e-bulletin *Tawasol*. They also benefitted from training by members of the National MS Society (USA) on their MS Navigator information and advice programme for possible use in Saudi Arabia.

We facilitated discussions amongst several MS organisations in the region about their experiences of MSIF's capacity building work. After this we worked with the organisations in the region to develop a multi-year regional capacity building framework focusing on access to treatment and care. To support this, we made an analysis of data about the Arab region in the Atlas of MS relating to access issues.

The National Belgian MS Society contributed £20,000 to support our work with MS organisations in Maghreb and MENA, an example of how members mutually support each other in building a stronger global MS movement.

In the second half of the year the Abu Dhabi Crown Prince Court asked us to provide advice on the setting up of an MS Society in the United Arab Emirates. For this purpose, our CEO, Peer Baneke, was invited to attend the F1 races in Abu Dhabi in December, to meet at high level in the margins of these and participate in a workshop about the development of the society.

Asia

In Asia we continued working with the MS Society of India (MSSI), supporting their 'Creating Young MS Leaders for Tomorrow' programme, a series of six online workshops. We also supported their 'numbers matter campaign, which included a unique, crowd-sourced India MS Map, to collect data from people with MS across the country, and a petition asking the government to create a national MS database.

Enhance the effectiveness of members and MSIF, including through our International Networking Meetings

Due to the impact of the COVID-19 pandemic, the functioning of many of our member organisations and thereby their capacity to support people affected by MS continued to be severely challenged, also by the impossibility to undertake any in-person fundraising during 2021. To mitigate this, we set up the system of COVID-19 Response Grants which we allocated in 2020 with the member organisations that benefitted from the grants continuing their implementation of the funded projects until the end of 2021.

In 2021 we held two International Networking Meetings in a virtual manner, built around our board meetings, and bringing together CEO's from our member organisations and people affected by MS on our People with MS Advisory Committee. Two additional virtual board meetings took place, one in June and one in December.

We made extensive use throughout the year of online communications, collaboration tools to facilitate communication and collaborative working between different functional groups within our member organisations to exchange experience and take global projects, such as those on access and data sharing forward.

In October, 83 people from 29 countries gathered together for MSIF's People with MS Forum: Building Connections. During the online event, participants sang, exchanged experiences on the impact of the pandemic on life with MS and had the opportunity to influence the global strategy for the MS movement.

Implement the 'more than one member per country' policy

In 2019 the membership policy was changed to allow more than one organisation per country to become a member of MSIF. Whilst we received several applications we suspended consideration of all applications during the course of 2020 as the staff normally dealing with this refocused on the response to COVID-19. We re-started the process in 2021 and granted full membership to the Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques (ARSEP) based in France. The Asociación Esclerosis Múltiple España (EME) Asociación Esclerosis Múltiple España (EME) was granted associate membership status.

To contribute to our aim of: Access to accurate and trustworthy information and resources to make informed decisions to live well with MS.
We set objectives for 2021 to:

- Repurpose and translate one or two materials for adaptation and use around the world.
- Maintain networks of membership staff and volunteers in communications.

Global information statements

MSIF continued to bring together global experts to develop advice about COVID-19 for people with MS. In 2021 this included information about the COVID-19 vaccines and MS, and was updated as new vaccines were approved around the world, and as new data becomes available.

International Resource Development

In response to feedback from a number of members, we produced a set of guidelines to help them decide on how best to acknowledge funding from pharmaceutical companies. The guidance relates to funding for information resources, webinars, event promotions and related materials. The guidance is formatted around traffic lights, showing the ideal, the acceptable and the situation to avoid.

The MS Resource Hub, a searchable tool on MSIF's website that signposts to information resources from member organisations around the world, has grown significantly since its launch in April 2020. The platform now signposts to around 320 information resources, contributed by 25 member organisations. We are continuing to add resources to the Hub and gather materials from members not currently featured on the platform. In this way the use of the best national materials in the global MS movement is extended for the benefit of many more MS organisations and through them many more people affected by MS around the world.

There has been significant engagement from across the MSIF movement with the 'Fatigue: an invisible symptom of MS' guide. A number of MS organisations have translated and adapted the guide and its accompanying fatigue diary. It is freely available in 11 languages: Arabic, Czech, English, Icelandic, Indonesian, Polish, Russian, Serbian, Slovak, Spanish and Urdu.

Maintain networks of membership staff and volunteers in communications

The key network of staff and volunteers in communications is the International Resource Group. We have held virtual meetings with them throughout 2021.

To contribute to our aim of: Positive changes in policies and practices, attitudes and behaviours that are obstacles to living well with MS

We set objectives for 2021 to:

- Develop advocacy tools for national, local and individual action, in particularly by coordinating World MS Day and continuing the work on an update of the Atlas of MS.

Develop advocacy tools for national, local and individual action

The advocacy tools we developed and or worked on in 2021 related to World MS Day and the Atlas of MS.

World MS Day

The theme for World MS Day 2020-2022 is ‘connections’. The MS Connections campaign is all about building community connection, self-connection and connecting to quality care.

May 2021 marked the second step in our three-year campaign. The continuing pandemic gave the theme great significance. Although it was chosen in 2019, the theme spoke directly to a rise in social isolation and healthcare barriers experienced by the MS community. MS organisations were extremely agile in adapting campaign plans to the new landscape. As in 2020, in-person events were replaced with online alternatives.

It was the biggest campaign since we launched World MS Day in 2009. It was celebrated across 117 countries, with participation from 840 organisations. There were 8 countries where World MS Day activity took place for the first time or the first time in a number of years: Ghana, Jamaica, Nepal, Bermuda, Burundi, Zambia, Philippines and the Vatican. Like in 2020 a virtual concert **Tune in for MS** took place with viewers from 54 countries. The global MS choir delivered a performance of Beautiful Day, with choir participants commenting on the power of gathering as an international community.

Atlas of MS

The first Edition of the Atlas of MS was first launched in 2008 in conjunction with the WHO, followed by a second edition in2013. The third edition was split in several parts, the first of which focused on epidemiology and was launched in 2020. Part 2 focuses on the diagnosis and treatment of MS and it was launched in April 2021 via a trilingual (English, Spanish, Arabic) webinar, attended by over 100 participants from 49 countries. One of the key findings of the second part of the Atlas was that more than three quarters of countries worldwide face issues that prevent early diagnosis of MS.

All the data can be viewed and downloaded from www.atlasofms.org including country factsheets in English, Spanish and Arabic.

At their invitation we partnered with the World federation of Neurology (WFN) to focus World Brain day 2021 on MS, including an awareness raising campaign and a global webinar.

We are developing mechanisms to enable annual updates of the core epidemiology statistics without having to wait several years for the next edition.

Resourcing the Strategy

Our Finance Committee met via video conference four times throughout the year. The meetings included examination of the management accounts and budget figures for 2022 alongside preliminary figures through to the end of 2024. These figures were presented to and subsequently approved by the Board.

Performance of material fundraising against fundraising objectives

Our budgeted income for 2021 was £585,000 from the healthcare industry and £1,740,000 from other sources (individuals, companies, member organisations, trusts and foundations, the May50k and other digital sources), altogether a total of £2,325,000.

During the year we raised a total of £2,275,250: £557,133 from healthcare companies, representing 24.5% of total income; other income raised of £1,718,117 towards our programmes includes 38% from the May50K, 25.4% from members and 12.1% from other sources.

In total we raised £49,450 less than our target. This was a mixture of less income from facebook (despite a lower target than last year) and DIY fundraising as well as some events being cancelled and expenditure on programme activities changing due to continued covid-19 restrictions, which had an impact on funding requests.

Impact of fundraising expenditure on current and future income

The total cost of direct fundraising activities was £16,597 under budget, at £292,073 for 2021. Around two-thirds of these costs was for income generated in 2022 and around one third was an investment in future income, in particular continued investment for the May50K fundraising programme in 2022 and Cykelnerven our cycling fundraising programme.

Investment performance against objectives set

The priorities for MSIF fundraising in 2021 were to continue to:

- Increase current income levels
- Grow newer income streams in particular, Cykelnerven, DIY fundraising, and the May 50K campaign.

For the second year running we had to cancel Cykelnerven with the continuation of restrictions due to the pandemic and our DIY fundraising was also impacted. However, income from the May50K increased to £865,585 from £731,887. Plans for the future were reviewed following the campaign in June 2021 which will also be used to inform our discussions over the coming months to set objectives for the next strategic period.

Managing external relationships

MSIF maintained and developed existing relationships with donors and sponsors, including companies within the healthcare industry, individuals and foundations.

Protecting vulnerable people

MSIF employs three fundraising staff and, through its community fundraising and digital fundraising platforms (such as Against MS, and Kiss Goodbye to MS) it encourages members of the public to fundraise from their networks and through third party events. In 2020 there were three areas of MSIF's fundraising which have the potential to impact vulnerable people; MSIF's fundraising platforms, participation in third party events and web donations.

As we didn't conduct any email fundraising in 2021, making donations through the web was entirely voluntary and donors must have a credit card or PayPal account to complete a transaction. Both of these require a bank account, which have safeguarding practices of their own.

MSIF's digital fundraising platforms and marketing of the third-party events both used social media, but both involve personal communication with MSIF. Through the donor support programme, we interact directly with the individuals creating pages or signing up for events and staff are instructed to speak to the Director of Fundraising & Engagement if they have any concerns about an individual. We communicate with Facebook donors and audiences through the Facebook platform, both as a group to encourage fundraising and individually after they have donated. Facebook's own safeguarding policies therefore apply.

It is unlikely to be known when a donation is received that it is from a vulnerable person. However, MSIF is committed to protecting vulnerable people and if we are alerted to donation from a vulnerable person, or if a staff member has concerns, the Acceptance and refusal of donations policy (section 4.4) details the process that MSIF will adopt.

Regulations, standards and schemes

MSIF is subject to the UK Charity Commission and the Fundraising Regulator, plus the Information Commissioner's Office. MSIF has also published its Supporter promise on its website, which outlines the key principles by which we operate. We have a Data protection policy and a Data security policy. All of the policies relating to public fundraising are available on the MSIF website.

Complaints

Our complaints policy and procedure are signposted on our website. We define a complaint in broad terms as 'any expression of dissatisfaction about any aspect of MSIF and its work with the global MSIF movement'. In 2021 we received 14 complaints, compared to 43 in 2020.

Financial review

Income was £49,450 lower than budgeted. This was largely due to cancellation of Cykelnerven and the impact of expenditure reductions on some funding requests in relation to COVID-19.

Expenditure was £386,145 lower than budgeted. With the inability to travel and hold in person meetings and activities expenditure anticipated for conferences and meetings, travel and professional fees were all reduced.

Overall with lower expenditure as well we ended the year with a surplus of £119,475.

As at 31 December 2021 we have unspent restricted funds of £776,078 and unrestricted funds of £845,487 and a designated fund of £60,000 towards a potential office move at the end of our current lease in 2024.

The reserves policy aims to reduce the unrestricted reserves over time to represent half a year of core running costs (staff and overheads).

Looking ahead, 2022 priorities

Long term Aims in the 2017-2021 Strategy	2022 objectives and actions towards these aims
Better scientific understanding leading to new ways to treat, prevent and stop MS.	• Advance systems for enabling data sharing, with a focus on Patient Reported Outcomes and the relationship between MS and COVID-19. • Continue to engage member organisations in and facilitate global communications about the Progressive MS Alliance. • Fill gaps in the MS research workforces throughout the world.
Improved access to effective treatments and health care.	• Continue work toward ensuring access to DMTs, including to a new application for the WHO's Essential Medicines List. • Use the Atlas to collect some more global data and publish the data gathered in 2020 in relation to access to treatment.
Access to accurate and trustworthy information and resources to make informed decisions to live well with MS.	• Repurpose and translate one or two materials for adaptation and use around the world. • Maintain networks of membership staff and volunteers in communications.
Positive changes in policies and practices, attitudes and behaviours that are obstacles to living well with MS	• Develop advocacy tools for national, local and individual action, in particularly by coordinating World MS Day and continuing the work on updates of the Atlas of MS.
A stronger, broader MSIF movement made up of effective MS organisations, engaged individuals and strategic international collaborations	• Strengthen MS organisations in countries with challenging socio-economic conditions, with a continued focus on the Arab region, Latin America and India. • Enhance the effectiveness of members and MSIF, including through our International Networking meetings. Implement the 'more than one member per country' policy.

In 2022 we will hold at least two board and global networking meetings, one in a virtual manner and one, hopefully in person. We will report progress against the above objectives and actions in the 2022 Report and Annual Accounts.

Audit information

So far as each of the directors at the time the trustees' report is approved is aware:

a) there is no relevant information of which the auditors are unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

Auditors

The auditors, Moore Kingston Smith LLP, are deemed to be reappointed under section 487(2) of the Companies Act 2006.

Note of appreciation

We would like to offer our thanks for the generosity and support received from the people affected by MS, national MS society staff and volunteers, scientists and other professionals, together with our corporate and individual donors and sponsors who enable us to continue our activities.

Statement of trustees' responsibilities

The trustees (who are also directors of the Multiple Sclerosis International Federation for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.
In preparing this report the Trustees have taken advantage of the small companies exemptions provided by section415A of the Companies Act 2006.

On behalf of Trustees

Mai Sharawy

Mai Sharawy, Chair

Date: 29/09/2022

Independent auditor’s report to the members of Multiple Sclerosis International Federation

Opinion

We have audited the financial statements of Multiple Sclerosis International Federation (‘the company’) for the year ended 31 December 2021 which comprises of the Statement of Financial Activities, the Summary Income and Expenditure Account, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company’s affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.
Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made;
- we have not received all the information and explanations we require for our audit.
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a Strategic Report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Moore Kingston Smith LLP

Luke Holt (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Date: 17 February 2023

Devonshire House
60 Goswell Road
London
EC1M 7AD

Statement of Financial Activities for the year ended 31 December 2021

	Note	Unrestricted Funds	Restricted Funds	2021 Total Funds	2020 Total Funds
		£	£	£	£
Income and Expenditure					
Income from:					
Donations	2	46,330	1,874,603	1,920,933	2,478,676
Income from charitable activities					
Membership dues		354,119	-	354,119	338,878
Investment Income				-	
Bank Interest		198	-	198	1,662
Total income		**400,647**	**1,874,603**	**2,275,250**	**2,819,216**
Expenditure on:					
Raising funds		292,073	-	292,073	215,648
Charitable activities					
Stopping MS		-	783,640	783,640	512,857
Improving access to treatment		-	287,591	287,591	161,486
Supporting informed decision making		69,902	142,702	212,604	177,431
Changing policies and practices		40,589	100,577	141,166	257,613
Stronger, broader MSIF movement		57,746	380,955	438,701	977,399
Total expenditure	**3 & 4**	**460,310**	**1,695,465**	**2,155,775**	**2,302,434**
Net income/(expenditure)		(59,663)	179,138	119,475	516,782
Net movement in funds		(59,663)	179,138	119,475	516,782
Reconciliation of funds:					
Total funds brought forward		965,150	596,940	1,562,090	1,045,308
Total funds carried forward at 31 December 2021	**10**	**905,487**	**776,078**	**1,681,565**	**1,562,090**

All gains and losses arising in the period have been included in the Statement of Financial Activities and relate to continuing operation.

The accompanying notes on pages 27 to 45 are an integral part of these financial statements.

Balance Sheet as at 31 December 2021

	Note	2021 £	2020 £
Fixed Assets:			
Tangible Assets			
Equipment	**6**	3,683	2,519
		3,683	**2,519**
Current Assets:			
Debtors & prepaid expenses	**7**	560,627	507,467
Cash at bank & in hand	**8**	2,020,490	1,939,424
		2,581,117	**2,446,891**
Creditors: Amounts falling due within one year	**9**	(903,235)	(887,320)
Net current assets		**1,677,882**	**1,559,571**
Total Net Assets	**10**	**1,681,565**	**1,562,090**
The funds of the charity:			
Unrestricted funds		845,487	925,150
Designated fund	**11**	60,000	40,000
Restricted funds	**12**	776,078	596,940
		1,681,565	**1,562,090**

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The accompanying Notes on pages 27 to 45 are an integral part of these financial statements.

The accounts were approved by the Board and authorised for issue on 28/09/2022 and signed on its behalf by:

V. Annis

Victoria Annis
Treasurer

Cash Flow Statement for the year ended 31 December 2021

	2021 £	2020 £
Cash generated from / (used in) operating activities		
Net cash (used in)/provided by operating activities	84,503	864,282
Cash flows from investing activities		
Dividends, interest and rents from investments	198	1,662
Purchase of property, plant and equipment	(3,635)	(3,779)
Net cash provided by/(used in) investing activities	(3,437)	(2,117)
Change in cash and cash equivalents in the reporting period	81,066	862,165
Cash and cash equivalents at the beginning of the reporting period	1,939,424	1,077,259
Cash and cash equivalents at the end of the reporting period	**2,020,490**	**1,939,424**

Reconciliation of net income/(expenditure) to net cash flow from operating activities

	2021 £	2020 £
Net income/(expenditure) for the reporting period (as per the statement of financial activities)	119,475	516,782
Adjustments for:		
Depreciation charges	2,471	4,589
Dividends, interest and rents from investments	(198)	(1,662)
(Increase)/decrease in debtors	(53,160)	(183,528)
Increase/(decrease) in creditors	15,915	528,101
Net cash provided by/(used in) operating activities	84,503	864,282

Prior Year Statement of Financial Activities

	Note	Unrestricted Funds £	Restricted Funds £	2020 Total Funds £
Income and Expenditure				
Income from:				
Donations	**2**	51,718	2,426,958	2,478,676
Income from charitable activities				
Membership dues		338,878	-	338,878
Investment Income				-
Bank Interest		1,662	-	1,662
Other				
Meeting Income		-	-	-
Total income		**392,258**	**2,426,958**	**2,819,216**
Expenditure on:				
Raising funds		215,559	89	215,648
Charitable activities				
Stopping MS		-	512,857	512,857
Improving access to treatment		-	161,486	161,486
Supporting informed decision making		42,663	134,768	177,431
Changing policies and practices		46,800	210,813	257,613
Stronger, broader MSIF movement		58,264	919,135	977,399
Total expenditure	**3 & 4**	**363,286**	**1,939,148**	**2,302,434**
Net income/(expenditure)		28,972	487,810	516,782
Net movement in funds		28,972	487,810	516,782
Reconciliation of funds:				
Total funds brought forward		936,178	109,130	1,045,308
Total funds carried forward at 31 December 2020	**10**	**965,150**	**596,940**	**1,562,090**

All gains and losses arising in the period have been included in the Statement of Financial Activities and relate to continuing operation

Notes to the financial statements

1. Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), published on 16 July 2014. The Charitable Company is a public benefit group for the purposes of FRS 102 and therefore the charity also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011.

Currency

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest pound.

Going concern

The financial statements have been prepared on a going concern basis.

Having carried out a detailed review of the Charity's resources and the current economic challenges, particularly in relation to COVID19, facing both the Charity and its members the Trustees are satisfied that the Charity has sufficient cash flows to meet its liabilities as they fall due for at least one year from the date of approval of the financial statements.

Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the board is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are outlined below.

Useful economic lives

The annual depreciation charge for property, plant and equipment is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 6 for the carrying amount of the property, plant and equipment. The useful economic lives is currently three years and depreciation is provided on fixed assets in excess of £1,000.

Incoming resources

Income is recognised in the accounting period to which it relates. Membership dues, legacies and meeting income are accounted for when entitled, can be reasonably measured and the receipt is probable. Donated services are valued at the advised commercial rate.

Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Wherever possible costs are directly attributed to these headings. The costs of generating funds are those costs of seeking potential funders and applying for funding. Support costs are those costs incurred in support of the charitable objectives. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Grant making policy

Grants are awarded by the Board to both individual and institutional recipients on the basis of their work. See Trustees' Report for detailed information.

Fund accounting

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors. The aim and use of each restricted fund is set out on the following pages.

Foreign currency

Transactions in foreign currency during the year are converted at the rate ruling at the date of transaction and any exchange differences arising are taken to the Statement of Financial Activities.

2 Donations

	Unrestricted Funds £	Restricted Funds £	Total 2021 £	Total 2020 £
Ares Trading SA	-	152,645	152,645	149,747
Biogen Intl GmbH	-	13,127	13,127	421,358
Bristol Myers Squibb	-	63,094	63,094	141,440
Coloplast		-	-	25,000
Genzyme	-	88,267	88,267	145,000
Janssen	-	15,000	15,000	
MS Organisations - ECTRIMS	-	64,000	64,000	63,995
MS Organisations - MENACTRIMS			-	-
donation in kind	-	7,350	7,350	-
MS Societies	-	450,426	450,426	172,424
Novartis	-	80,000	80,000	100,000
Roche	-	110,000	110,000	220,000
Vanneau Trust	-	150,000	150,000	220,000
Viatris (formerly Mylan)		35,000	35,000	15,000
Torn Gaming Community-in memoriu	12,515		12,515	-
Other	33,815	645,694	679,509	804,712
	46,330	**1,874,603**	**1,920,933**	**2,478,676**

Personal donations from Trustees during the period amounted to £633

Prior Year Donations

	Unrestricted Funds £	Restricted Funds £	Total 2020 £	Total 2019 £
Ares Trading SA	-	149,747	149,747	167,473
Biogen Intl GmbH	-	421,358	421,358	56,250
Bristol Myers Squibb (Celgene - 201	16,040	125,400	141,440	56,413
Coloplast		25,000	25,000	-
Donation in kind	-	-	-	15,000
Genzyme	-	145,000	145,000	160,194
Hertie ^	-	-	-	32,045
Med Day	-	-	-	15,000
MS Organisations - ECTRIMS	-	63,995	63,995	63,995
MS Societies	-	172,424	172,424	364,687
MS Society donation in kind	-	-	-	106,481
Mylan		15,000	15,000	-
Novartis	-	100,000	100,000	60,000
Roche	-	220,000	220,000	40,000
Vanneau Trust	-	220,000	220,000	188,400
Wolfensohn Family Foundation*	-	-	-	7,537
Other	35,678	769,034	804,712	135,950
	51,718	**2,426,958**	**2,478,676**	**1,469,425**

Personal donations from Trustees during the period amounted to £2,109

* Income received from CAF

^ Income received from the German MS Society

3 Expenditure

	Direct Activities £	Grant Funding £	Support Costs £	Total 2021
Raising funds				
Raising funds	257,888	-	34,185	292,073
Charitable activities				
Stopping MS	27,444	437,136	319,060	783,640
Improving access to treatment	93,800	28,564	165,227	287,591
Supporting informed decision making	47,376	-	165,228	212,604
Changing policies and practices	33,593	5,019	102,554	141,166
Stronger, broader MSIF movement	51,595	33,861	353,245	438,701
	511,696	**504,580**	**1,139,499**	**2,155,775**

Grants payable comprises:	Grants to Institutions £	Grants to Individuals £	Total £
Stopping MS	434,136	3,000	437,136
Access to treatment	9,582	18,982	28,564
Changing policies and practices	5,019	-	5,019
Stronger, broader MSIF movement	33,861	-	33,861
	482,598	**21,982**	**504,580**

Grants payable to institutions comprises:	Grants £
Progressive MS Alliance - National MS Society, USA	256,136
University of California San Francisco, USA	32,000
MS Society, Belgium	1,000
Azienda Sanitaria, Italy	8,563
Mcmaster University, Canada	1,019
MSSI, India	15,730
Amsterdam University Medical Centre, Netherlands	32,000
Brighams and Women's Hospital USA	32,000
University College London, UK	32,000
ABEM, Brazil	500
San Rafaelle University, Italy	32,000
Pitie Salpetriere Hospital, France	6,000
University of Alberta, Canada	6,000
Unie Roska Czech, Republic	1,000
MS Society, Greece	1,000
Charite Universitatsmedizin, Germany	6,000
EMA, Argentina	5,150
Renacer, Dominican Republic	3,500
APEMED, Paraguay	5,000
ALEM, Columbia	6,000
Total £	**482,598**

3 Expenditure continued

Grants payable outstanding comprises:

	Grants £
Progressive MS Alliance - National MS Society, USA	256,136
Pitie Salpetriere Hospital, France	6,000
University of Alberta, Canada	6,000
Charite Universitatsmedizin, Germany	6,000
San Rafaelle University, Italy	32,000
Pitie Salpetriere Hospital, France	6,000
University of Alberta, Canada	6,000
Amsterdam University Medical Centre, Netherlands	32,000
Brighams and Women's Hospital USA	32,000
University College London, UK	32,000
University of California San Francisco, USA	32,000
	446,136

Prior Year Expenditure

	Direct Activities £	Grant Funding £	Support Costs £	Total 2020 £
Raising funds				
Raising funds	173,259	-	42,389	215,648
Charitable activities				
Stopping MS	13,466	266,251	233,140	512,857
Improving access to treatment	66,108	-	95,378	161,486
Supporting informed decision mɑ	39,668	-	137,763	177,431
Changing policies and practices	76,934	5,821	174,858	257,613
Stronger, broader MSIF movement	51,161	550,032	376,206	977,399
	420,596	**822,104**	**1,059,734**	**2,302,434**

Grants payable comprises:

	Grants to Institutions £	Grants to Individuals £	Total £
Stopping MS	264,751	1,500	266,251
Changing policies and practices	3,140	2,681	5,821
Stronger, broader MSIF movement	550,032	-	550,032
	817,923	**4,181**	**822,104**

Prior year expenditure continued

Grants payable to institutions comprises:	Grants £
Progressive MS Alliance - National MS Society, USA	94,251
University of California San Francisco, USA	64,000
MS Society, Portugal	59,200
MS Society, Belgium	58,400
MS Ireland	54,400
MS Society, Switzerland	47,500
MS Society, Germany	45,000
MSSI, India	41,670
MS Society, Spain (AEDEM)	40,000
LFSEP, France	37,000
University of Basel, Switzerland	32,000
San Raffelle Hospital, Italy	32,000
ABEM, Brazil	29,500
Polskie Towarzystwo Stwardnienia Rozsianego, Poland	26,000
EME, Spain	20,790
UK MS Society	14,000
MS Society, Cyprus	14,000
MS Society, Greece	12,240
MS Society of Austria	11,600
EMA, Argentina	10,000
MS Society, Lithuania	8,400
Hellenic Federation of Persons with MS	8,200
ASOGEM, Guatemala	7,700
ASOGEM, Guatemala 2019	(2,000)
ICM, Paris France	6,000
Mcgill University, Canada	6,000
John Hopkins School of Medicine, USA	6,000
Koç University Research Center for Translational Medicine, Turkey	6,000
APEMED, Paraguay	5,387
MS Society, Latvia	5,000
The British Hospital of Buenos Aires Argentina	4,500
Fumasep and Rahma, Morocco	3,127
ATSEP, Tunisia	3,100
Macedonia National Association for MS	3,000
MS New Zealand	1,000
ALSEP, Lebanon	1,000
NORD.MA.SEP, Morocco	840
ALEM, Columbia	800
MS Society Queensland, Australia	318
Total £	**817,923**

4 Breakdown of expenditure

	Raising Funds	Stopping MS	Improving access to treatment	Supporting informed decision making	Changing policies & practices	Stronger, broader MSIF movement	Total 2021
	£	£	£	£	£	£	£
Direct Activities							
Conferences & Meetings	725	3,697	0	160	0	7,370	11,952
Travel & Accommodation	0	0	0	0	0	485	485
Professional Fees	256,534	21,199	91,600	47,216	33,593	43,740	493,882
Printing & Publications	629	2,548	2,200	-	0	-	5,377
Grants (note 3)	-	437,136	28,564	-	5,019	33,861	504,580
Sub Total	**257,888**	**464,580**	**122,364**	**47,376**	**38,612**	**85,456**	**1,016,276**
Support Costs							
Staff Costs (note 5)	28,652	267,423	138,485	138,483	85,956	296,076	955,075
Governance Costs	273	2,547	1,317	1,318	819	2,820	9,094
Education & Training	160	1,490	773	771	479	1,651	5,324
Rent, Rates & Insurance	3,423	31,954	16,548	16,547	10,271	35,376	114,119
Premises Maintenance	425	3,958	2,047	2,052	1,271	4,383	14,136
IT Support & Maintenance	906	8,459	4,380	4,382	2,719	9,364	30,210
Office Expenses	53	491	260	257	160	546	1,767
Financial Expenses	219	2,045	1,059	1,060	657	2,263	7,303
Depreciation (note 6)	74	693	358	358	222	766	2,471
Sub Total	**34,185**	**319,060**	**165,227**	**165,228**	**102,554**	**353,245**	**1,139,499**
Total Expenditure	**292,073**	**783,640**	**287,591**	**212,604**	**141,166**	**438,701**	**2,155,775**

Auditors' Fees during the period amounted to £6,400 + VAT. Auditors' Other Services during the period amounted to £800. (2019 - Auditors' Fees £5,150 + VAT. Auditors' Other Services - Nil)

Support costs including governance costs are apportioned on the basis of staff time

The above expenditure includes unrestricted expenditure of £363,286 (2019: £667,590) and restricted expenditure of £1,939,148 (2019: £1,356,708)

4 Prior year breakdown of expenditure

	Raising Funds	Stopping MS	Improving access to treatment	Supporting informed decision making	Changing policies & practices	Stronger, broader MSIF movement	Total 2020
	£	£	£	£	£	£	£
Direct Activities							
Conferences & Meetings	301	2,947	233	203	3,015	237	6,936
Travel & Accommodation	1569	6,045	425	751	1,826	111	10,727
Professional Fees	171,192	4,458	65,450	38,714	69,893	50,813	400,520
Printing & Publications	197	16	-	-	2,200	-	2,413
Grants (note 3)	-	266,251	-	-	5,821	550,032	822,104
Sub Total	**173,259**	**279,717**	**66,108**	**39,668**	**82,755**	**601,193**	**1,242,700**
Support Costs							
Staff Costs (note 5)	34,934	192,135	78,601	113,534	144,101	310,038	873,343
Governance Costs	545	2,998	1,227	1,771	2,249	4,838	13,628
Education & Training	131	719	294	424	539	1,162	3,269
Rent, Rates & Insurance	4,668	25,678	10,502	15,172	19,258	41,431	116,709
Premises Maintenance	636	3,502	1,435	2,073	2,625	5,653	15,924
IT Support & Maintenance	1,083	5,958	2,437	3,520	4,469	9,613	27,080
Office Expenses	61	331	138	195	252	537	1,514
Financial Expenses	147	809	331	478	608	1,305	3,678
Depreciation (note 6)	184	1,010	413	596	757	1,629	4,589
Sub Total	**42,389**	**233,140**	**95,378**	**137,763**	**174,858**	**376,206**	**1,059,734**
Total Expenditure	**215,648**	**512,857**	**161,486**	**177,431**	**257,613**	**977,399**	**2,302,434**

Auditors' Fees during the period amounted to £6,400 + VAT. Auditors' Other Services during the period amounted to £600. (2019 - Auditors' Fees £5,150 + VAT. Auditors' Other Services - Nil)

Support costs including governance costs are apportioned on the basis of staff time

The above expenditure includes unrestricted expenditure of £363,286 (2019: £667,590) and restricted expenditure of £1,939,148 (2019: £1,356,708)

5 Staff Costs

	2021 £	2020 £
Salaries	818,096	741,410
Social Security	81,971	82,105
Pensions and Other Costs	55,008	49,828
	955,075	**873,343**

The average number of employees during the year was 19. The average number of part time employees was 6, with their full time equivalent being 5. (2020 The average number of employees during the year was 19. The average number of part time employees was 6, with their full time equivalent being 5).

One employee received total taxable emoluments of between £90,000 and £99,999 during the year (2020 one £90,000 - £99,999) and defined contributions of £5,703 to a pension scheme (2020 £5,616).
One other employee received total taxable emoluments between £60,000-£69,999 (2020 one £60,000-£69,999) and defined contributions of £3,879 to a pension scheme. (2020 - one £3,812).

A defined contribution pension scheme is provided. The costs for the period were £44,869, of which £4,411 was outstanding at the balance sheet date. (2020 The costs for the period were £42,821, of which £421 was outstanding at the balance sheet date).

Key Management Personnel
Key management personnel include the Trustees and senior management. The total employee benefits, including pension costs and employer's national insurance, of the charity's key management personnel were £214,178 (2020: £211,433).

No Trustee received any remuneration from the charity in the period. During the period no Trustees received travel expenses. (2020 - six trustees received £1,428).

6 Fixed Assets

	Equipment £
Cost brought forward at 1 January 2021	38,166
Additions	3,635
Disposals	-
Cost/depreciation carried forward at 31 December 2021	**41,801**
Depreciation brought forward at 1 January 2021	35,647
Depreciation for the year	2,471
Disposals	-
Cost/depreciation carried forward at 31 December 2021	**38,118**
Net Book Value at 31 December 2021	**3,683**
Net Book Value at 31 December 2020	**2,519**

7 Debtors and Prepaid Expenses

	2021 £	2020 £
Other Debtors	489,261	436,683
Prepayments	59,864	60,867
VAT Reclaimable	11,502	9,917
	560,627	**507,467**

8 Cash at bank and in hand.

	2021 £	2020 £
Bank Accounts	2,020,413	1,939,342
Cash	77	82
	2,020,490	**1,939,424**

9 Creditors: Amounts falling due within one year

	2021 £	2020 £
Deferred income	110,012	23,094
Other creditors	282,391	396,684
Accruals	510,832	467,542
	903,235	**887,320**

Please refer to note 3 to see which grants are included in the Accruals and Other Creditors balances

10 Analysis of Net Assets between Funds

	Unrestricted £	Restricted £	Total £
Fixed Assets	3,683	-	3,683
Current Assets	1,805,039	776,078	2,581,117
Current Liabilities	(903,235)	-	(903,235)
	905,487	**776,078**	**1,681,565**

Prior Year Analysis of Net Assets between Funds

	Unrestricted £	Restricted £	Total 2020 £
Fixed Assets	2,519	-	2,519
Current Assets	1,849,951	596,940	2,446,891
Current Liabilities	(887,320)	-	(887,320)
	965,150	**596,940**	**1,562,090**

11 Designated fund movement

	Balance 01.01.21 £	Resources Incoming £	Resources Outgoing £	Transfers £	Balance 31.12.21 £
Unrestricted	925,150	400,647	(460,310)	(20,000)	845,487
Designated fund:					
Provision for potential office move	40,000	-	-	20,000	60,000
	965,150	**400,647**	**(460,310)**	-	**905,487**

Expenditure is anticipated in 2024 when our current lease expires

Prior Year Designated fund movement

	Balance 01.01.20 £	Resources Incoming £	Resources Outgoing £	Transfers £	Balance 31.12.20 £
Unrestricted	916,178	392,258	(363,286)	(20,000)	925,150
Designated fund:					
Provision for potential office move	20,000	-	-	20,000	40,000
	936,178	**392,258**	**(363,286)**	**0**	**965,150**

12 Outline summary of restricted fund movements

	Balance 01.01.21 £	Resources Incoming £	Resources Outgoing £	Balance 31.12.21 £
Research fellowships & grants	940	225,640	226,580	-
Strategy & research coordination	110,152	2,096	60,676	51,572
Progressive MS	473	301,243	301,716	-
Data sharing	137	47,990	48,127	-
Increasing resources	485	33,700	34,185	-
Improving access to treatment	405,127	483,056	244,206	643,977
Mena access to treatment	18,000	45,385	43,385	20,000
Resource development	-	62,577	62,577	-
Digital communications	-	47,577	47,577	-
MSIF Communications	-	32,548	32,548	-
World MS Day	-	100,577	100,577	-
Atlas	29,494	88,449	112,356	5,587
Global capacity building	-	115,632	115,632	-
Response Initiative - Covid19	13,608	-	13,608	-
Regional Programmes - Arab Region	2,383	87,143	44,584	44,942
Regional Programmes - Asia	-	60,356	60,356	-
Regional Programmes - Latin America	3,804	105,634	99,438	10,000
Skills networking	12,337	35,000	47,337	-
	596,940	**1,874,603**	**1,695,465**	**776,078**

Prior Year Outline summary of restricted fund movements

	Balance 01.01.20 £	Resources Incoming £	Resources Outgoing £	Balance 31.12.20 £
Research fellowships & grants	23,677	177,652	200,389	940
Strategy & research coordination	12,002	190,846	92,696	110,152
Progressive MS	39	148,747	148,313	473
Data sharing	4,332	46,067	50,262	137
Increasing resources	638	21,044	21,197	485
Improving access to treatment	-	566,613	161,486	405,127
Resource development	-	54,917	54,917	-
Digital communications	-	54,918	54,918	-
MSIF Communications	-	24,933	24,933	-
World MS Day	4,500	105,155	109,655	-
Atlas	35,942	94,644	101,092	29,494
Global capacity building	-	58,033	58,033	-
Response Initiative - Covid19	-	570,617	557,009	13,608
Regional Programmes - Arab Region	8,000	117,700	105,317	20,383
Regional Programmes - Asia	-	45,089	45,089	-
Regional Programmes - Latin America	20,000	130,931	147,127	3,804
Skills networking	-	18,897	6,560	12,337
Other	-	155	155	-
	109,130	**2,426,958**	**1,939,148**	**596,940**

The purposes of the restricted funds are as follows:

Stopping MS

Research Fellowships & Grants: McDonald Fellowships are awarded to young researchers from emerging countries for research in MS. The two-year award includes a grant to cover travel and living costs, and an additional contribution of £2,000 per year to the host laboratory. The total award is a maximum of £30,000 per annum with up to three fellowships per year.

Du Pre Grants enable young researchers to undertake short visits to MS research centres of excellence. Each grant is £1,000 - £6,000 to cover travel costs or as a top-up to an existing grant. MSIF makes up to 5 grants per year. The Charcot Award is awarded for a lifetime achievement in outstanding research into the understanding or treatment of MS. The winner gives the Charcot Lecture at ECTRIMS. Their travel costs, and expenses are covered, up to a maximum of £5,000. A grant of £1,500 is awarded to the winner.

Strategy & research coordination: Facilitate, co-fund, cooperate and support common action by national MS organisations in relation to international research programmes/conferences. This involves the International Research Staff Network, International Medical and Scientific Board (IMSB) and liaison with the international MS research community.

Data Sharing: The programme of work encompasses our support for an international initiative to establish a global consensus around patient reported outcomes, and also our participation or collaboration in any internationally relevant initiatives about sharing research/patient/clinical data relevant to MS.

Increasing resources: This programme of work aims to support encourage and support our member organisations to raise more funds for research. The most prominent part of this programme is the global Kiss Goodbye to MS campaign that focuses mostly on raising funds for research.

Progressive MS: Activities and support related to progressive MS as well as to the Alliance with sixteen of our member organisations to expedite the research into treatments for progressive MS.

Improving Access

Improving access to treatment: This programme aims to improve access for people with MS to all forms of healthcare, medical treatment and MS drugs around the world, that are effective, affordable, and of reliable quality.

Capacity building for access: Bring together MS organisations in the MENA region to increase and strengthen regional communication and cooperation, improve staff/volunteers' advocacy skills and increase capacity of MS organisations in this area.

Treatment information: Attend meetings and calls to contribute to the development of international guidelines on MS and provide funds to translate resulting materials.

Supporting informed decision making

Resource development: Repurpose and translate information materials for adaption and use around the world.

Digital communications: Any digital communication, including keeping MSIF's website up to date with free, trusted information about research, treatment and other aspects of MS, as well as MSIF's and our member's activities, for use by member organisations and other groups and individuals throughout the world. Prepare, send and translate (into Spanish and Arabic) MSIF's e-newsletters: Making Connections and Research News.

Skills Networks: Building the MSIF movement's capacity in communications, care and services through establishing and strengthening networks of relevant staff and volunteers from MS organisations and bringing them together to share skills and experience, proving training and development with the potential to develop international collaborative projects or replicate and adapt high quality projects in multiple countries.

MSIF communications: Funds for communications about the organisation itself, such as banners or materials and attendance at international conferences.

Changing policies and practices

World MS Day: World MS Day (30 May) is an opportunity for people worldwide to join the global MS movement and participate in events and activities to raise awareness of MS as a global issue.

Atlas: The Atlas of MS presents data on the global, regional and national epidemiology of MS, and the resources available for the treatment, management, rehabilitation and support of people with MS in every country with a significant prevalence of MS. Individuals, groups and organisations use it as a tool to illustrate the results of comparative analysis of epidemiology and resource data across geographical areas.

Wolfensohn Award: The James D Wolfensohn Award is given to support people with and affected by MS to travel to participate in international meetings and activities in recognition of their valuable contribution to the fight against MS. Nominations are submitted to MSIF's Person's with MS Committee to select the winner. Every two years people with and affected by MS gather to give direct input into the work of the Global MSIF movement at the People with MS Forum facilitated by MSIF.

Advocacy: Includes the Quality of Life Principles - a framework that sets out what is required for people with MS to have the best possible quality of life.

Stronger, broader MSIF movement

Global and other countries: building capacity, by supporting member organisations, amongst others through coaching, visits, exploring new partnerships and providing travel grants for attendance at meetings.

Regional Programmes - Arab Region: Build capacity, by initiating or supporting the development of MS organisations in Arabic speaking countries.

Regional Programmes - Latin America: Build capacity by supporting the development of MS organisations in Latin America.

Regional Programmes – Asia: Build capacity, by initiating or supporting the development of emerging MS support structures and groups and MS organisations in Asia, including through small grants for workshops, world MS Day activities and newsletters.

Skills networking: To provide opportunities for the membership to learn about each other’s areas of work and share best practice.

The May 50K: a virtual international event under the umbrella of Kiss Goodbye to MS, which enables people around the world to raise funds for vital research into MS and support people living with MS today.

13 Future Commitments

At 31 December 2021, MSIF had total minimum lease payments under operating leases as set out below:

	2021 £	2020 £
Equipment		
Less than one year	175	700
One to two years	1,225	175
Land and Buildings		
Less than one year	83,374	83,374
One to five years	86,343	169,717
	171,117	**253,966**

14 Related Party Disclosures



Name of Entity	Nature of Relationship	Membership Dues Received 2021 £	Membership Dues Received 2020 £
MS Society, Australia	Joint Trustee and Chair	58,943	46,428
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Joint Trustee and Chair	8,308	8,308
MS Society of Canada	Joint Trustee	33,335	-
MS Society Denmark	Joint Trustee	-	14,340
MS Care, Egypt	Joint Trustee and Chair	12	12
Ligue Francaise contre la Sclerose En Plaques, France	Joint Trustee	6,544	6,544
MS Society India	Joint Trustee and Chair	-	495
MS society Italy	Joint Trustees and Chair	-	33,347
Esclerosis Multipla Espana, Spain	Joint Trustee	598	598
National MS Society, USA	Joint Trustees and Chair	110,004	110,019



Name of Entity	Nature of Relationship	Membership Dues Accrued 2021 £	Membership Dues Accrued 2020 £
MS Society Greece	Joint Trustee	298	298
MS Society India	Joint Trustee	550	-
MS Society Denmark	Joint Trustee	-	14,340
MS Society Italy	Joint Trustees and Chair	27,789	27,789
Esclerosis Multipla Espana, Spain	Joint Trustee	-	498

Related Party Disclosures Continued

Name of Entity	Nature of Relationship	Grants Received 2021 £	Grants Received 2020 £
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Member	-	20,000
Ligue Française contre la Sclérose En Plaques, France	Joint member Progressive MS Alliance	-	17,420
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Member	64,000	63,568
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Joint member Progressive MS Alliance	51,802	-
Swiss MS Society, Switzerland	Joint member Progressive MS Alliance	63,966	-
MS Society Iceland	Joint member Progressive MS Alliance	-	577
MS Ireland	Joint member Progressive MS Alliance	1,698	6,210
MS Ireland	Member	75,804	-
Stichting MS Research, Netherlands	Member	151,906	-
Esclerosis Multipla Espana, Spain	Joint member Progressive MS Alliance	41,250	49,429
MS Society, UK	Member	-	10,000
National MS Society, USA	Member	-	5,220

Name of Entity	Nature of Relationship	Grants Paid 2021 £	Grants Paid 2020 £
Progressive MS Alliance - National MS Society, USA	Joint member	256,136	94,251
EMA, Argentina	Member	5,150	10,000
MS Society, Austria	Member	-	11,600
Ligue National Belge de la Sclersoe en Plaques, Belgium	Member	1,000	58,400
ABEM, Brazil	Member	500	29,500
Unie Roska Czech, Republic	Member	1,000	-
MS Society, Cyprus	Member		14,000
LFSEP, France	Member		37,000
MS Society, Germany	Member		45,000
MS Society, Greece	Member	1,000	12,240
ASOGEM, Guatemala	Member		7,700
MS Society, India	Member	15,730	41,670
MS Ireland	Member		54,400
MS Society, Latvia	Member		5,000
ALSEP, Lebanon	Member		1,000
MS Society, New Zealand	Member		1,000
Polskie Towarzystwo Stwardnienia Rozsianego, Poland	Member		26,000
MS Society, Portugal	Member		59,200
AEDEM, Spain	Member		40,000
EME, Spain	Member		20,790
MS Society, Switzerland	Member		47,500
ATSEP, Tunisia	Member		3,100
UK MS Society	Member		14,000

Prior Year Related Party Disclosures

Name of Entity	Nature of Relationship	Membership Dues Received 2020 £	Membership Dues Received 2019 £
MS Society, Australia	Joint Trustee and Chair	46,428	45,513
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Joint Trustee and Chair	8,308	8,145
MS Society of Canada	Joint Trustee	-	32,693
MS Society Denmark	Joint Trustee	14,340	10,489
MS Care, Egypt	Joint Trustee and Chair	-	12
Ligue Francaise contre la Sclerose En Plaques, France	Joint Trustee	6,544	6,544
MS Society India	Joint Trustee and Chair	495	495
MS society Italy	Joint Trustees and Chair	-	32,693
Stichting MS Research, Netherlands	Joint Trustee	-	6,360
Esclerosis Multipla Espana, Spain	Joint Trustee	-	586
National MS Society, USA	Joint Trustees and Chair	110,019	110,004

Name of Entity	Nature of Relationship	Membership Dues Accrued 2020 £	Membership Dues Accrued 2019 £
EMA, Argentina		90	-
MS Society, Canada		33,347	-
Union of Estonian Multiple Sclerosis Societies		-	19
MS Society Egypt	Joint Trustee and Chair	12	-
MS Society France (ARSEP)		1,489	-
MS Society Greece	Joint Trustee	298	293
MS Society Guatemala		12	12
MS Society Iceland		-	895
MS Society India		-	550
MS Society Israel		-	352
MS Society Italy	Joint Trustees and Chair	27,789	-
Multiple Sclerosis Society Malta		18	18
MS Society New Zealand		703	703
MS Society Portugal		948	948
Esclerosis Multipla Espana, Spain	Joint Trustee	498	-
MS Society Turkey		626	626

Prior Year Related Party Disclosures

Name of Entity	Nature of Relationship	Grants Received 2020 £	Grants Received 2019 £
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Member	20,000	-
Scleroseforeningen, Denmark	Member	-	8,039
Neuroliitto, Finland	Member	-	429
Ligue Française contre la Sclérose En Plaques, France	Joint member Progressive MS Alliance	17,420	-
Ligue Française contre la Sclérose En Plaques, France	Member	-	1,305
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Joint member Progressive MS Alliance	-	103,466
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Member	63,568	63,448
DMSG Germany	Member	-	32,045
MS Society Iceland	Joint member Progressive MS Alliance	577	-
MS Ireland	Joint member Progressive MS Alliance	6,210	12,842
MS Ireland	Member	-	1316
MS Society Italy	Member	-	33,850
Stichting MS Research, Netherlands	Member	-	2,107
Stichting MS Research, Netherlands	Joint member Progressive MS Alliance	-	42,312
MS Society New Zealand	Member	-	376
Esclerosis Multipla Espana, Spain	Joint member Progressive MS Alliance	49,429	78,244
Esclerosis Multipla Espana, Spain	Member	-	-
MS Society, UK	Member	10,000	10,000
National MS Society, USA	Member	5,220	113,433

Prior Year Related Party Disclosures

Name of Entity	Nature of Relationship	Grants Paid 2020 £	Grants Paid 2019 £
Progressive MS Alliance - National MS Society, USA	Joint member	94,251	260,210
EMA, Argentina	Member	10,000	
MS Society, Austria	Member	11,600	-
Ligue National Belge de la Sclerose en Plaques, Belgium	Member	58,400	-
ABEM, Brazil	Member	29,500	-
MS Society, Cyprus	Member	14,000	-
LFSEP, France	Member	37,000	-
MS Society, Germany	Member	45,000	-
MS Society, Greece	Member	12,240	1,000
ASOGEM, Guatemala	Member	7,700	2,000
MS Society, India	Member	41,670	9,062
MS Ireland	Member	54,400	-
MS Society, Latvia	Member	5,000	-
ALSEP, Lebanon	Member	1,000	600
MS Society, New Zealand	Member	1,000	-
Polskie Towarzystwo Stwardnienia Rozsianego, Poland	Member	26,000	900
MS Society, Portugal	Member	59,200	600
AEDEM, Spain	Member	40,000	-
EME, Spain	Member	20,790	-
MS Society, Switzerland	Member	47,500	-
ATSEP, Tunisia	Member	3,100	-
UK MS Society	Member	14,000	-
Esclerosis Múltiple Uruguay	Member	-	900

15 Company Limited by Guarantee

Every full voting member undertakes to contribute such amount as may be required (not exceeding £10) to the company's assets if it should be wound up while it is a full voting member or within 1 year afterwards, (2021 33 members (2020 - 32 members)).